Skip to main content

Table 4 Patient and tumour characteristics in the 2nd line endocrine setting (n = 6)

From: Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors

Variable -2nd line n (%), median (range)
Median age at AI initiation 56 years (40–74)
Performance status  
0 2 (33%)
1 4 (67%)
Menopausal status  
Premenopausal 1 (17%)
Postmenopausal 5 (83%)
Number of co-morbidities  
0-1 5 (83%)
2-3 1 (17%)
Sites of metastases at time of AI initiation  
Lung 4 (67%)
[Lung as only site of metastases] 4 (67%)
Peritoneum/pelvis 2 (33%)
Tumour volume at time of AI initiation  
Low 2 (33%)
High 4 (67%)
Histological grade (Stanford)  
Low 5 (83%)
High 1 (17%)
Hormone receptor status  
ER  
Moderate to strong (grade 2–3) 5 (83%)
Weak (grade 1) 1 (17%)
PgR  
Moderate to strong (grade 2–3) 4 (67%)
Weak (grade 1)/ NA 2 (33%)
ER and PgR  
Moderate to strong (grade 2–3) 4 (67%)
Weak (grade 1) 1 (17%)
% ER staining  
>90% 5 (83%)
unknown 1 (17%)
% PgR staining  
>90% 2 (33%)
>50% 3 (50%)
0% 1 (17%)
unknown 2 (33%)
  1. AI, aromatase inhibitor; ER, oestrogen receptor; PgR, progesterone receptor.